Ibalizumab plus an optimized background regimen in treatment-experienced patients infected with multidrug resistant HIV-1: A phase 3, multicenter, expanded access study.
Emu B, Kumar P, Mills A, Berhe M, Cash B, Kuo K, Anstett K. Ibalizumab plus an optimized background regimen in treatment-experienced patients infected with multidrug resistant HIV-1: A phase 3, multicenter, expanded access study. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2025 PMID: 40465394, DOI: 10.1097/qai.0000000000003699.Peer-Reviewed Original ResearchMultidrug-resistant HIV-1Treatment-emergent adverse eventsCD4+ cell countMultidrug resistanceHIV-1Viral loadTreatment optionsDiscontinuations due to treatment-emergent adverse eventsSuppression of viral replicationSafety of long-term useCell countEffective suppression of viral replicationOptimized background regimenTreatment-experienced patientsBaseline to weekPoor clinical outcomesResistant HIV-1Exposure to drugsStudy initiationBackground regimenLong-term useOpen-labelRNA copies/mLPatterns of resistanceMechanism of action
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply